Protects against two wild-type strains and an F1-negative strain
The same Israeli groups, with two mRNAs rather than one: F1 and LcrV, including an antibody-Fc design meant to improve the response. An April 2025 paper reported protection of mice against pneumonic challenge with two wild-type strains and a strain that makes no F1 capsule. Still preclinical. It is the second of the three RNA programmes in the set.
Preclinical · pneumonic. Phase 3 is empty here, as it is for every programme in the set.
A mark at 2025. Labelled “Apr 2025” on the briefing. Not a forecast.
Analyst card
- Pneumonic mouse model. Two wild-type strains and one F1-negative strain. Septicemic disease is not separated.
- Shown in mice. The April 2025 paper included an F1-negative challenge.
- Lipid nanoparticles. An Fc-fusion design is part of the construct.
- Not stated beyond the mRNA doses used in the mouse study.
- mRNA. Ultra-cold requirement is not stated.
- Not reported. No time-to-protection figure is in the briefing.
- Plague only.
- Protection was reported. A single survival percentage is not restated in this briefing. Challenge dose is not either.
- Mouse data only. Not an Animal Rule file.
Pipeline record
- The same Israeli groups as the single-antigen mRNA.
- Two mRNAs, F1 and LcrV, including an antibody-Fc design.
- April 2025. Mice. Pneumonic challenge with two wild-type strains and a strain that makes no F1 capsule.
- Still preclinical. The second of the three RNA programmes.
News
Checking today’s headlines.
Latest intel
Checking Europe PMC.
PubMed
Checking today’s index.
- mRNA
Messenger RNA in lipid nanoparticles instructs cells to make plague antigens for a short time. Both programmes in this set are still preclinical.
- Israel — IIBR (Prime Minister's Office) + Tel Aviv Univ.
- Israel
- Pneumonic
- Preclinical · pneumonic
- Apr 2025
- F1V / LcrV